NewEdge Advisors LLC Has $3.51 Million Position in GSK PLC Sponsored ADR $GSK

Key Points

• NewEdge Advisors LLC increased its ownership in GSK PLC by 8.6% during the first quarter, owning a total of 90,663 shares valued at approximately $3.5 million.
• GSK's quarterly earnings surpassed expectations, reporting an EPS of $1.23 against a consensus estimate of $1.12, and a revenue of $10.64 billion.
• The company declared a quarterly dividend of $0.4206, with an annualized yield of 4.1%, and a payout ratio of 77.78%.

NewEdge Advisors LLC grew its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 8.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,663 shares of the pharmaceutical company's stock after purchasing an additional 7,148 shares during the quarter. NewEdge Advisors LLC's holdings in GSK were worth $3,512,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. HHM Wealth Advisors LLC raised its holdings in shares of GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC bought a new position in GSK in the 1st quarter worth $31,000. Richardson Financial Services Inc. raised its holdings in GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares during the period. Olde Wealth Management LLC bought a new position in GSK in the 1st quarter worth $36,000. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in GSK by 525.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares during the period. Institutional investors own 15.74% of the company's stock.

GSK Stock Performance

NYSE GSK traded down $0.67 during midday trading on Friday, hitting $40.81. The company had a trading volume of 4,741,956 shares, compared to its average volume of 3,553,270. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The stock has a market cap of $83.12 billion, a price-to-earnings ratio of 18.89, a P/E/G ratio of 2.07 and a beta of 0.53. The firm has a fifty day simple moving average of $38.69 and a two-hundred day simple moving average of $38.44. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $43.62.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. During the same period last year, the business posted $0.43 EPS. The business's quarterly revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a dividend yield of 4.1%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is 77.78%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on GSK shares. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Six investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.